MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
7.34
+0.16
+2.23%
After Hours: 7.34 0 0.00% 18:19 04/02 EDT
OPEN
7.05
PREV CLOSE
7.18
HIGH
7.45
LOW
7.04
VOLUME
28.53K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
2.860
MARKET CAP
83.87M
P/E (TTM)
-1.2099
1D
5D
1M
3M
1Y
5Y
1D
Kazia Therapeutics files Form 3 as David Cain named Director, CMC
Reuters · 3d ago
Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
TipRanks · 3d ago
Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE
TipRanks · 5d ago
Weekly Report: what happened at KZIA last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at KZIA last week (0316-0320)?
Weekly Report · 03/23 09:08
Kazia Therapeutics Posts Wider Half-Year Loss but Bolsters Cash, Pipeline and Nasdaq Compliance
TipRanks · 03/19 21:27
Kazia Therapeutics Director Steven R. S. Coffey Files Initial Beneficial Ownership Statement
Reuters · 03/18 23:18
Kazia Therapeutics files initial beneficial ownership statement for CEO John E. Friend II
Reuters · 03/18 22:36
More
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.